Access and Evidence
Quest for Available Drug Data Continues
The on-going battle for clinical trial data continues with calls from the European Parliament for drug makers to make full results widely available.
More Access and Evidence Articles
Access and Evidence
US Consumers Have Rosy View of Drug Costs
A new study from the W. P. Carey School of Business at Arizona State University shows consumers believe prices for essential medicines are based on public need and not profit.
Access and Evidence
Public Education: The Solution for Real World Evidence Privacy Concerns
Rochelle Sampy speaks to Richard Bergström, Director General of the European Federation of Pharmaceutical Industries and Associations about the benefits Real World Evidence can bring to healthcare and how to alleviate very valid concerns about data privacy.
Access and Evidence
The Patent War: MNCs Change Their Battle Strategy in India
With the Indian government continuing to favor generics in their quest for affordable healthcare, pharma multinationals are now opting for aggressive preemptive strikes to protect profits via India's courts.
Access and Evidence
Experts Call on FDA for Changes To “Unsafe” Medical Device Approvals
An academic perspective published in the New England Journal of Medicine makes an urgent call to the FDA to prevent unsafe medical devices from entering the marketplace.
Access and Evidence
China Proposes Fast-Tracking Registration for “High-priority” Generics
China’s State Food and Drug Administration has announced proposals to reform the country’s drug registration process, including a special “fast-track” for generics which answer an unmet clinical need.
Access and Evidence
More Targeted, Personalised Treatments Expected from Pharma R&D Pipeline
Pharmaceutical companies are moving away from developing ‘blockbuster’ drugs to creating new targeted biopharmaceutical treatments for ‘niche’ diseases, according to recent research.
Access and Evidence
FDA Standards no Longer a Pain for NuPathe
The US Food and Drug Administration (FDA) has – for the first time – approved a patch that delivers the active drug transdermally to relieve migraine-related symptoms.
Access and Evidence
Health Committee Calling for a New Code of Practice
The Health Committee at the UK’s National Institute for Health and Clinical Excellence has urged the industry to rebuild trust with professionals and the public by making all clinical trial data available.
Access and Evidence
Merck’s Whistle Blowing Just Got Louder
After a storm of commotion in light of Merck & Co’s drug Tredaptive, which was found (when added to statins) not to reduce major vascular events as it’s supposed to, the company has taken it upon themselves to update the public on the latest developments.